eClinical Technology and Industy News

A New Class of Antiviral Therapy Could Treat COVID-19

Excerpt from the Press Release:

As the SARS-CoV-2 virus mutates, new variants emerge that can better evade immunity and spread more widely. This causes an ongoing race, in which scientists and pharmaceutical companies must continually test and adapt vaccines to keep up with the latest variant of the virus. This is similar to how the flu vaccine must be redesigned each year to match the newest strains—except that SARS-CoV-2 evolves faster than the flu.

Using a fundamentally different approach, scientists at Gladstone Institutes discovered a new type of antivirals that can track the evolution of the virus, which significantly reduces the chance that new variants could reduce the efficacy of the treatment.

In a new study published in the journal Cell, the researchers engineered a single-dose treatment for SARS-CoV-2 that can be delivered intranasally. Their novel approach is based on the concept of therapeutic interfering particles, often called TIPs, which was pioneered by Gladstone Senior Investigator Leor Weinberger, PhD.

He and his team report the discovery of the first TIP, showing it can inhibit SARS-CoV-2 and its variants, and withstand the virus’s ability to evolve new resistant variants. They showed, in animals, that TIPs dramatically reduced the amount of SARS-CoV-2 virus found in the lungs and protected the animals from disease.

“The past 2 years have impressed upon the world how much we need new antiviral strategies,” says Harmit Malik, PhD, professor at the Basic Sciences Division at Fred Hutchinson Cancer Research Center in Seattle, who was not involved in the study. “The design and use of TIPs has always held incredible promise of providing a simple-to-administer, highly effective antiviral strategy that can resist viral adaptation. This study is a true inflection point, showing that the powerful TIPs technology is not just theoretically possible, but imminently within reach.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives